Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT05536141 2026-03-30

ARC-20

Phase 1 Recruiting

362 enrolled

Genitourinary

Erythrocytosis, Familial, 4, Carcinoma, Renal Cell, Kidney Neoplasms

NCT06759649 2026-02-27

A Clinical Trial to Assess COM503 in Participants With Advanced Solid Malignancies

Phase 1 Recruiting

200 enrolled

Tumor-Agnostic

Neoplasms

NCT05840224 2026-01-28

Study of GS-4528 in Adults With Solid Tumors

Phase 1 Active not recruiting

182 enrolled

Other solid neoplasm

Solid Tumor

NCT05007782 2025-12-29

Study of Denikitug (GS-1811) Given Alone or With Zimberelimab in Adults With Advanced Solid Tumors

Phase 1 Recruiting

416 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT04772989 2025-08-28

ARC-12

Phase 1 Completed

94 enrolled

DermatologicGastrointestinalGynecologicLymphoidPlasma cellThoracic

Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Lymphoma, Non-Hodgkin, Melanoma, Multiple Myeloma, Stomach Neoplasms, Lymphoma, Large B-Cell, Diffuse

NCT03628677 2025-02-04

A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies

Phase 1 Completed

75 enrolled

Other solid neoplasm

Solid Tumor, Unspecified, Adult

NCT03846310 2024-12-09

ARC-4

Phase 1 Completed

77 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04087018 2024-09-19

Study to Evaluate Safety and Clinical Activity of AB122 in Biomarker Selected Participants With Advanced Solid Tumors

Phase 1 Completed

18 enrolled

Other solid neoplasm

Advanced Solid Tumors

NCT04747470 2024-09-03

Study to Assess the Effects of GS-3583 in Participants With Advanced Solid Tumors

Phase 1 Terminated

13 enrolled 18 charts

Other solid neoplasm

Advanced Solid Tumors

NCT03629756 2024-05-24

A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies

Phase 1 Completed

48 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Ovarian Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms

NCT03713905 2023-04-10

Study of Recombinant Human Anti-PD-1 Monoclonal Antibody for Patients With Advanced Solid Tumors

Phase 1 Completed

293 enrolled

Other solid neoplasm

Advanced Solid Tumors

Clinical Trials

Study of GS-2121 Given Alone or in Combination in Adults With Advanced Solid Tumors

Study of GS-9911 With or Without Antibody Treatment for Adults With Solid Tumors

ARC-8

ARC-25

ARC-20

A Clinical Trial to Assess COM503 in Participants With Advanced Solid Malignancies

Study of GS-4528 in Adults With Solid Tumors

Study of Denikitug (GS-1811) Given Alone or With Zimberelimab in Adults With Advanced Solid Tumors

ARC-12

A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies

ARC-4

Study to Evaluate Safety and Clinical Activity of AB122 in Biomarker Selected Participants With Advanced Solid Tumors

Study to Assess the Effects of GS-3583 in Participants With Advanced Solid Tumors

A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies

Study of Recombinant Human Anti-PD-1 Monoclonal Antibody for Patients With Advanced Solid Tumors